CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST. A live webcast of the TD Cowen presentation will be available here and the replay will be available on the Company’s ...

Cerus Corporation (NASDAQ:CERS) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President & Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to Cerus Corporation Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Af ...

ITEM 1. FINANCIAL STATEMENTS 1 2 Cerus Corporation Shareholders See accompanying Notes to Condensed Consolidated Financial Statements. Note 1. Summary of Significant Accounting Policies The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related ...

Cerus Corporation (NASDAQ:CERS) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Jessica Hanover - Vice President-Corporate Affairs Obi Greenman - president and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Laurence Corash - Chief Scientific Officer Conference Call Participants Jacob Johnson - Stephens Mathew Blackman - Stifel Joshua Jennings - TD Cohen Operator Good day, ladies and gentlemen. Thank you for standing by ...

• comply with requirements established by the FDA, including post-marketing requirements and label restrictions; and • comply with other U.S. healthcare regulatory requirements. 36 We are exposed to risks associated with the highly concentrated market for the INTERCEPT Blood System. 37 Our research and development activities involve the controlled use of hazardous materials, including certain hazardous chemicals, radioactive materials and infectious pathogens, such as HIV and hepatitis viruses. Although we ...

Cerus Corporation (NASDAQ:CERS) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Jessica Hanover – Vice President-Corporate Affairs Obi Greenman – President and Chief Executive Officer Vivek Jayaraman – Chief Operating Officer Kevin Green – Chief Financial Officer Conference Call Participants Brandon Folkes – Cantor Fitzgerald Matt Blackman – Stifel Operator Good day, and welcome to the Cerus Corporation’s First Quarter 2023 Earnings Conference Call. At this time all participant ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common Stock, pa ...

Cerus Corp (NASDAQ:CERS) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Joel Trujillo - Senior Director, IR William Greenman - President, CEO & Director Vivek Jayaraman - COO Kevin Green - VP, Finance & CFO Carol Moore - SVP, Regulatory Affairs, Quality & Clinical Conference Call Participants Mathew Blackman - Stifel, Nicolaus & Company Jacob Johnson - Stephens Inc. Brandon Folkes - Cantor Fitzgerald Joshua Jennings - Cowen and Company Operator Good day, ladies and gentle ...

60 See Note 7, Debt, in Part IV, Item 15, "Exhibits and Financial Statement Schedules" of this Annual Report on Form 10-K for more information on the debt under our Term Loan Credit Agreement and the Revolving Loan Credit Agreement. Critical Accounting Policies and Management Estimates Results of Operations Cost of Product Revenue Research and Development Expenses uncertainties associated with the successful completion of our research and development projects, which risks and uncertainties are discussed in ...

Cerus Corporation (NASDAQ:CERS) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Jessica Hanover - Vice President, Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Brandon Folkes - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the Cerus Corporation’s Quarter Three 2022 Earnings Conference C ...